ECM Weekly (4th July 2021) - Xpeng, Medbot, Medlive, Brii Bio, CTOS, LinkDoc, Devyani, Manycore
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
448 Views
3SBio Inc (1530.HK) - The Concerns and the Outlook
This insight mainly analyzed the potential reasons behind the decline in 3SBio Group's share price, the important products, the pipeline, the...
257 Views
ECM Weekly (27th June 2021) - Didi, Xpeng, Zylox, Dingdong, EBeauty, Chaoju Eye Care, Keymed Bio
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
420 Views
Keymed (康诺亚生物) IPO: A Free Option for Overseas Potential
Keymed's IPO valuation only reflects the value derived from China market. The value derived from the overseas market will be the free option for...
525 Views
Keymed (康诺亚生物) Pre-IPO: Differentiated Products but Far from Commercialization
We highlight that Keymed is led by experienced management team with strong R&D track record which is evidenced by its differentiated product pipeline.
366 Views